tbuckley/cabot-search huggingface dataset:
Chronic granulomatous disease 1974
Authors: R. J. Schlegel
Journal: JAMA (1975)

THE office diagnosis of many newly discovered diseases caused by neutrophil dysfunction is now possible with the use of clinical criteria and relatively simple laboratory tests. Through techniques evolved in the course of elucidating rare inborn disorders, it is now feasible to approach commonplace impairments of neutrophil function which occur as secondary consequences of other diseases or of chemotherapy. The advances were initiated, in part, by the recognition of a clinical entity, chronic granulomatous disease (CGD). Although a condition featuring hypergammaglobulinemia and chronic infection had been recognized by Janeway in Boston, and the inflammatory hallmark defined histopathologically as suppurative granulomata by Landing and Shirkey<sup>1</sup>in Los Angeles, it was the intuitive perception of Good and his colleagues, Bridges and Berendes,<sup>2</sup>and, later, Quie et al,<sup>3</sup>which resulted in the definition:<i>an inherited condition in which the neutrophils could engulf, but not kill, infectious microorganisms</i>. Subsequently, Quie and
The susceptibility of young adult Americans to vaccine-preventable infections. A national serosurvey of US Army recruits
Authors: P W Kelley, B P Petruccelli, P Stehr-Green, R L Erickson, C J Mason
Journal: JAMA (1991)

<h3>Objective.</h3> —Due to recent resurgences of measles, mumps, and rubella among young US adults, we sought to generate antibody prevalence data for national and military immunization policy evaluations. <h3>Design.</h3> —We used a questionnaire and serological survey of Army recruits to assess antibody status to measles, mumps, rubella, and varicella by enzymelinked immunosorbent assay and to poliovirus types 1,2, and 3 by microneutralization assay. <h3>Setting.</h3> —Basic training reception centers at Fort Benning, Ga, and Fort Jackson, SC. <h3>Patients.</h3> —The study included 1547 US Army recruits who were inducted during September and October 1989. <h3>Outcome Measures.</h3> —Seronegativity by various demographic factors. <h3>Results.</h3> —Seronegativity rates, directly adjusted to the 15- to 24-year-old US population in 1980, were 20.7% for measles, 15.6% for mumps, 17.5% for rubella, and 6.9% for varicella. For measles, mumps, and rubella, susceptibility was less in females, blacks, and college-educated recruits, and varicella susceptibility was greater in females and blacks. Recruits who were born after 1969 lacked measles, mumps, and rubella antibodies more often than older recruits. The adjusted seronegativity rates for poliovirus types 1, 2, and 3 were 2.3%, 0.6%, and 14.6%, respectively; trends by age, sex, and race-ethnicity were generally unremarkable. <h3>Conclusions.</h3> —Among young adult Americans, susceptibility to measles, mumps, and rubella is unevenly distributed and may be substantial. Our findings support national objectives to further improve immunization coverage in schoolage and adult populations and provide further impetus for legislation requiring college entrants to present evidence of having received at least two doses of measles vaccine, with one on or after entry into elementary school. (<i>JAMA</i>. 1991;266:2724-2729)
A phase II trial of enzalutamide in patients with androgen receptor positive (AR+) ovarian, primary peritoneal or fallopian tube cancer and one, two, or three prior therapies.
Authors: Rachel N. Grisham, Dilip D. Giri, Alexia Iasonos, Qin Zhou, Jeffrey Girshman, Sean Patrick McGrath, Roisin Eilish O'Cearbhaill, Paul Sabbatini, William P. Tew, David Michael Hyman, Martee Leigh Hensley, Dmitriy Zamarin, Jason A. Konner, Alexandra Snyder Charen, Karen Anne Cadoo, David R. Spriggs, Gopa Iyer, Carol Aghajanian
Journal: Journal of Clinical Oncology (2017)

TPS5610 Background: Approximately 75% of women with epithelial ovarian cancer (OC) present with advanced disease. Most of these women will ultimately recur and require life-long treatment for their cancer. Well tolerated therapies for treatment in the recurrent setting are needed. The AR is expressed in greater than 60% of cases of OC and is more prevalent than the estrogen or progesterone receptor. All past clinical studies of AR inhibition in OC have focused on unselected populations of heavily pretreated women; however preclinical data suggests that AR expression decreases in OC cells with increasing lines of therapy. Enzalutamide is a small molecule androgen receptor-antagonist that is FDA approved for treatment of prostate cancer and is currently being investigated as treatment for breast and ovarian cancer. Methods: This is a phase II, single-institution trial of enzalutamide 160mg po QD in patients with AR+ ovarian, fallopian tube or primary peritoneal cancer. Eligible patients must be found to have greater than or equal to 5% AR staining by IHC on FFPE tumor tissue and been treated with only 1,2 or 3 prior cytotoxic therapies. Patients must have RECIST 1.1 defined measurable disease. Enrolled patients are treated with enzalutamide until progression of disease or unacceptable toxicity. The primary endpoint is to estimate the proportion of women who achieve a complete or partial response by RECIST 1.1 criteria or survive progression free for at least 6 months. Secondary objectives include the retrieval of optional tumor biopsies at time of progression to evaluate the effect of enzalutamide on AR expression and to observe the effect of enzalutamide on serum testosterone and estradiol levels. This study will enroll 58 patients at Memorial Sloan Kettering Cancer Center and its regional sites. The study utilizes a safety lead-in phase and a two-stage design. The first patient enrolled in April 2015. The safety lead-in phase has been completed. The prespecified activity goal for the first stage was met; second stage accrual began in October 2016. Thus far, 35 patients have initiated treatment. Clinical trial information: NCT01974765.
The Effects of Weather on Pain, Comfort and Efficiency
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Artificial Intelligence (AI) and machine learning (ML) in risk prediction of hospital acquired pressure injuries (HAPIs) among oncology inpatients.
Authors: Vinod Ravi, Jing Zheng, Aparna Subramaniam, Lavonia G Thomas, John Showalter, John Frownfelter, Kelly Miller
Journal: Journal of Clinical Oncology (2019)

309 Background: Utilizing AI and ML is an emerging method to improve risk identification, characterization and stratification for clinical outcomes such as HAPIs. The Jvion Cognitive Clinical Success Machine (CCSM) utilizes the Eigen Sphere technique to factor in clinical, socioeconomic, and behavioral covariates at the individual patient level to maximize accuracy of risk prediction and provide insights on prevention of HAPIs. Methods: A retrospective analysis was performed utilizing claims and EHR data on 63,476 inpatient admissions between June 2016 and June 2018 at M D Anderson Cancer Center, a 660-bed oncology facility (Table 1) . All risk assessment indicators in the data were removed prior to analysis by the CCSM to compute unbiased risk probabilities for HAPIs. The performance of the CCSM risk prediction for all new stage 2 and above HAPIs (&gt;=Stage 2 HAPIs) was compared with the Braden scale using AUC. Results: The Jvion CCSM had an AUC of 0.84 compared to the AUC of 0.72 for the Braden scale in the prediction of &gt;=Stage 2 HAPIs. Conclusions: The AUC indicates that the Jvion CCSM has better predictive accuracy than the Braden scale. It also has better discrimination in risk identification. Thus, Jvion CCSM can be a valuable tool in risk screening for HAPIs which can lead to early preventative interventions. Characteristics of admission records used to compare accuracy of Jvion CCSM and Braden scale in predicting new &gt;=Stage 2 HAPIs (N=58,228). [Table: see text]
Editorial Board
Authors: Daniel Cattran, P Coates, Andrew Davenport, Tilman Drueke, Paris Ckd, Associated Complications, Masaomi Nangaku, Jai Radhakrishnan, New York, Maria Rastaldi, Brian Reeves, Detlef Schlöndorff, Michael Ross, Qais Al-Awqati, York New, Christina Wyatt, Vic Hasselblad, Jacksonville Zhezhen, Joseph Kim, Yi-Ju Li, , Durham, Dorothea Nitsch, London Ramakrishnan, Anupam Agarwal, Hans Anders, Jonathan Barratt, Daniela Leicester, São Barreto, David Paulo, Tomas Basile, Francois Denver, Joseph Berthoux, Emmanuel Boston, São Burdmann, Giovambattista Paulo, Christos Napoli, Yi-Pu Paris, Erik Chen, Steven Christensen, New Coca, Terence York, London Cook, D Vivette, New Agati, Farhad York, John Danesh, Ian Chicago, Marc De Boer, Antwerp De Broe, Vikas Zurich, St Dharnidharka, Zheng Louis, Adriana Dong, Kai-Uwe Oviedo, Erlangen Eckardt, Eiam-Ong Somchai, Michael Emmett, Dallas Endre, Sydney Evan, Pieter Evenepoel, Sarah Leuven, Denver Faubel, Steven Faul, Danilo Mineola, Jürgen Homburg, Agnes Aachen, Alessia Nashville, Barry Miami, Winston-Salem Freedman, Isehara Masafumi Fukagawa, Vesna Garg, Rochester Garovic, Laguna Glassock, Glenda Niguel, David Gobe, New Goldfarb, Matthew York, Mark Griffin, Angeles Haas, John Haase, Cijiang He, Michelle Hladunewich, Thomas Hostetter, Chi-Yuan Cleveland, San Hsu, Tobias Francisco, Benjamin Huber, St Humphreys, Reiko Louis, Jula Tokyo, Dallas Inrig, Francisco Kirsten Johansen, Roberto Kamyar Kalantar-Zadeh, Iowa Kalil, Yashpal City, Chicago Kanwar, New Kaskel, Krzysztof York, York Kiryluk, Clayton Kitching, Matthias Kopp, Ann Kretzler, Christian Arbor, Christophe Bonn, Paris Legendre, Los Lemley, Adeera Angeles, Philip Levin, Hong Li, Christoph Kong, John Toronto, Rochester Lieske, Jiannong Little, Kathleen Liu, San Liu, Youhua Francisco, Zhi-Hong Liu, Nanjing Liu, Dallas Lu, Matthias Berlin, Johannes Mack, Peter Mann, Hamilton Margetts, Kunihiro Amiens, William Matsushita, Atlanta Mcclellan, Timothy Mehrotra, Palo Meyer, Jeffrey Alto, St Miner, William Louis, Houston Mitch, Jeremiah Moeller, St Morrissey, Rosa Louis, São Moysés, Rama Paulo, Peter Duarte, David Nelson, Clayton Nikolic-Paterson, Klaus Charlottesville, Juan Oliver, York Charles O'neill, Atlanta Panzer, Mark Perazella, New Haven, Janos Peti-Peterdi, Los Angeles, Laura Plantinga, Atlanta Pollak, Didier Boston, Ambra Charlottesville, Susan Pozzi, Chicago Quaggin, Jochen Reich, Giuseppe Reiser, Sharon Bergamo, Mariano Clayton, Mitchell Rodriguez, Robert Rosner, Simone Safirstein, New Sanna-Cherchi, Antonio York, Kai Santoro, New Schmidt-Ott, Kumar York, La Sharma, Edward Jolla, Katalin Siew, Philadelphia Susztak, C Sydney, Hong Tang, Ravi Kong, Joshua Boston, Jens Denver, Marcello Nashville, Frank Tonelli, Manjeri Van Der Sande, San Venkatachalam, Carsten Antonio, Joel Wagner, Ann Weinberg, Matthew Arbor, Donald Weir, Temple Wesson, Jack Westenfelder, Adam Wetzels, Myles Whaley-Connell, Keng-Thye Wolf, Kwan-Dun Woo, Taiwan Wu, Yusuke Suzuki, Tokyo Zeisberg
Journal: Kidney International (2016)
Menopause and Hypothalamic-Pituitary Sensitivity to Estrogen—Correction
Authors: Howard Ritter, Harvey Edmonds
Journal: JAMA (2005)

ming sperm." 1 This description is supremely felicitous, as the Veil Nebula is, in fact, the tattered remnants of a supernova-an exploding star.But there is a far deeper connection.The universe started with little other than hydrogen and helium, and none of the heavy elements of our familiar world and ourselves.The heavier elements up through iron are produced inside massive stars much heavier than the sun, by thermonuclear fusion during the stable portions of their lives.When such stars reach the end of their useable nuclear fuel, they become unable to sustain their own weight, collapse, and rebound in a titanic explosion.This blast, occupying the last few seconds of the star's existence, synthesizes the elements heavier than iron and blows the entire star, aside from the core, into free space, where the heavy elements enrich the hydrogen and helium of the pristine interstellar medium.The next generation of stars and planetary systems born of the enriched gas thereby possesses the heavy elements required for the formation of solid planets and for life.Thus are we all, as astrophysicists and songwriters are wont to say, stardust.In this sense, the supernova actually is how "life begins."The portion shown in the (much overexposed) photograph in the painting is called the Western Veil and is part of a larger complex called the Cygnus Loop, which is about 15000 years old, 2500 light years away, 4 times the apparent diameter of the full moon, but very faint.Examined at leisure through a large telescope, under dark and transparent skies, the Veil Nebula is a complex, subtle, and sublime sight.Excellent photographs of the Veil Nebula can be found at the Web site of the National Optical Astronomy Observatories.
News of risk as a potential stressor
Authors: M. Horowitz
Journal: JAMA (1985)

Medicine now takes aim at prevention of disease by early recognition of risk factors. While increased knowledge of dispositions to disorder may permit early intervention, it surely facilitates early diagnosis. Yet even these advances in knwoledge carry potential hazards for the patient. Informing a person that he is at higher than usual risk for serious illness, or perhaps premature death, may set loose a train of thought and emotions that could, in some, culminate in a stress response syndrome. Serious news of risk is incongruent with the current world view of an individual. Many persons regard themselves as invulnerable to illness and death, believing that such events only strike others. This usually unconscious and self-benevolent form of denial may be shattered when a physician informs a patient, on routine physical examination, that his or her blood pressure is dangerously elevated, that a painless mass may be cancerous, or that a
Association of Preoperative Anemia With Postoperative Mortality in Neonates—Reply
Authors: Susan M. Goobie, David Faraoni, James A. DiNardo
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Errors in Table.
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Correction.
Authors: H. O. Dalton
Journal: JAMA (1890)

<h3>To the Editor:</h3> —InThe Journalof the 18th inst., in the report of the Mississippi Valley Medical Association Proceedings, your reporter stated that I "reported six cases of gunshot injury of the abdominal cavity in which the viscera were injured, with five recoveries and one death." My paper was<i>confined</i>to the report of cases of penetrating<i>stab</i>wounds of the abdomen, and hence<i>gunshot</i>wounds were not considered. By correcting the mistake in your next issue you will oblige Very truly yours,
The Global HIV and AIDS Epidemic, 2001
Journal: JAMA (2001)

Human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) are pandemic and pose one of the greatest challenges to global public health. As a bloodborne and sexually transmitted infection, HIV has variable patterns of transmission and impact among world regions and has disproportionately affected disadvantaged or marginalized persons such as commercial sex workers, injection drug users, men who have sex with men (MSM), and persons living in poverty. HIV infection has caused approximately 20 million deaths; an estimated 36 million persons are infected (Figure 1). On the basis of data from the Joint United Nations Program on AIDS (UNAIDS) and other sources, this report summarizes epidemiologic trends, highlights several HIV and AIDS prevention milestones, and describes some prevention activities for the coming decade.
Monitoring
Authors: Z. Zivkovic, S. Mihailovic, O. Tosev, D. Semple, L. E. Wilson, Lynne W. Coule, Edward J. Truemper, Curt M. Steinhart, G. Ya Gebel, L. M. Golostenova, A. G. Kruglov, A. N. Dasaev, V. N. Utkin, V. E. Bagdatjev, N. G. Ignatov, S. G. Suvorov, Mark A. van der Hoeven, Wiel J. Maertzdorf, Carlos E. Blanco
Journal: Intensive Care Medicine (1996)
"A NEW METHOD OF TREATMENT FOR VARICOSE ULCERS OF THE LEG"
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NIMG-47. PHOTOPENIC DEFECTS ON O-(2-18F-FLUOROETHYL)-L-TYROSINE PET - CLINICAL RELEVANCE IN GLIOMA PATIENTS
Authors: Norbert Galldiks, Marcus Unterrainer, Natalie Judov, Gabriele Stoffels, Philipp Lohmann, Franziska Vettermann, Veronika Dunkl, Bogdana Suchorska, Joerg-Christian Tonn, Friedrich-Wilhelm Kreth, Gereon Fink, Peter Bartenstein, Karl-Josef Langen, Nathalie Albert
Journal: Neuro-Oncology (2017)

In PET imaging, a considerable number of gliomas shows no O-(2-18F-fluoroethyl)-L-tyrosine (FET) uptake compared to the healthy-appearing unaffected brain, including lesions with even less uptake (photopenic defects). The clinical relevance of photopenic defects remains to be elucidated. Glioma patients with a negative FET PET scan prior to histological confirmation were retrospectively identified in two university centers. Gliomas were visually rated as having indifferent FET uptake when no difference was found in comparison to the background activity, and as photopenic when FET uptake was below background acitivity. For the semiquantitative analysis, FET uptake in the area of signal hyperintensity on the T2-/FLAIR-weighted MRI was evaluated by mean standardized uptake values (SUV) and mean tumor-to-brain ratios (TBR). In patients without treatment (“watch and wait” strategy), the progression-free survival (PFS) of photopenic gliomas was compared with that of gliomas with indifferent FET uptake. Of 104 FET-negative gliomas (2 WHO grade I, 75 WHO grade II, 23 WHO grade III, and 4 WHO grade IV), 36 cases with photopenic defects (35%) were identified (23 WHO grade II, 12 WHO grade III, and one glioblastoma). FET uptake in photopenic defects was significantly decreased compared to both the healthy-appearing brain tissue (SUV, 0.88 ± 0.23 vs. 1.10 ± 0.26; P<0.001) and gliomas with indifferent FET uptake (TBR, 0.83 ± 0.10 vs. 1.03 ± 0.11; P<0.001). In patients without treatment (all WHO grade II; stereotactic biopsy only), PFS of those with indifferent FET-uptake (n=16) was significantly longer than with photopenic defects (n=10) (31 vs. 23 months; P=0.026). The age and rate of IDH mutations did not differ significantly in both groups (P>0.05). Around one-third of FET-negative gliomas exhibit photopenic defects. These photopenic gliomas should be managed more actively as they might have a higher risk for harbouring a higher-grade glioma and an unfavorable outcome compared to gliomas with indifferent FET uptake.
Association News.
Journal: JAMA (1901)

<h3>Chairmen of Committees of the American Medical Association.</h3> Dr. J. F. Fulton. Lowry Arcade, St. Paul, Minn., on arrangements. Dr. C. A. Wheaton, Lowry Arcade, St. Paul. Minn., on finance. Dr. J. W. Chamberlin, Lowry Arcade, St. Paul. Minn., badges. Dr. C. Williams. 145 West 5th street, St. Paul, Minn., banquets. Dr. H. L. Taylor. Lowry Arcade, St. Paul. Minn., general exhibits. Dr. H. H. Kimball, Dayton Building. St. Paul. Minn., meet ing places. Dr. Burnside Foster. Lowry Arcade. St. Paul, Minn., entertainments. Dr. Edw. Boeckmann. Lowry Arcade. St. Paul. Minn., pathological exhibits. Dr. J. A. Quinn, corner 4th street and Wabasha, St. Paul. Minn., transportation. Dr. Harry O'Brien, Endicott Arcade. St. Paul, Minn., programs and publications. Dr. J. T. Rogers, Lowry Arcade, St. Paul, Minn., halls and meeting places. Dr.